TY - JOUR
T1 - Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality
T2 - Findings from the Atherosclerosis Risk in Communities (ARIC) study
AU - Mannino, David M.
AU - Doherty, Dennis E.
AU - Buist, A. Sonia
N1 - Funding Information:
The authors thank the staff and participants in the Atherosclerosis Risk in Communities (ARIC) study for their important contributions. The ARIC study is conducted and supported by the National Heart Lung and Blood Institute (NHLBI) in collaboration with the ARIC Study Investigators. This Manuscript was not prepared in collaboration with investigators of the ARIC study and does not necessarily reflect the opinions or views of the ARIC study or the NHLBI.
PY - 2006/1
Y1 - 2006/1
N2 - Objective: To determine whether a modified Global Initiative on Obstructive Lung Diseases (GOLD) classification of chronic obstructive pulmonary disease (COPD) predicts mortality in a cohort of subjects followed for up to 11 years. Methods: We analyzed data from 15,759 adult participants, aged 43-66 years at baseline, in the Atherosclerosis Risk in Communities (ARIC) study. All baseline and follow-up data were available for 15,440 (97.9%) of the initial participants. We classified subjects using a modification of the GOLD criteria for COPD (prebronchodilator forced expiratory volume in 1 s (FEV1) stratification of disease severity), and added a "restricted" category (FEV1/FVC>70% and FVC<80% predicted). We used Cox proportional hazard models to determine the risk of impaired lung function on subsequent mortality, after adjusting for age, race, sex and smoking status. Results: 1242 (8.0%) subjects died by the end of 1997. The overall rate of death was 8.9 per 1000 person years, but varied from 5.4/1000 among normal subjects to 42.9/1000 among subjects with GOLD Stage 3 or 4 COPD. After adjusting for covariates, all GOLD categories, along with the restricted category, predicted a higher risk of death: GOLD Stage 3 or 4, hazard ratio (HR) 5.7, 95% confidence interval (CI) 4.4, 7.3; GOLD Stage 2 HR 2.4, 95% CI 2.0, 2.9; GOLD Stage 1 HR 1.4, 95% CI 1.1, 1.6; GOLD Stage 0 HR 1.5, 95% CI 1.3, 1.8; and restricted HR 2.3, 95% CI 1.9, 2.8. Conclusion: The modified GOLD classification system of COPD predicts mortality in this cohort of middle-aged Americans followed for up to 11 years.
AB - Objective: To determine whether a modified Global Initiative on Obstructive Lung Diseases (GOLD) classification of chronic obstructive pulmonary disease (COPD) predicts mortality in a cohort of subjects followed for up to 11 years. Methods: We analyzed data from 15,759 adult participants, aged 43-66 years at baseline, in the Atherosclerosis Risk in Communities (ARIC) study. All baseline and follow-up data were available for 15,440 (97.9%) of the initial participants. We classified subjects using a modification of the GOLD criteria for COPD (prebronchodilator forced expiratory volume in 1 s (FEV1) stratification of disease severity), and added a "restricted" category (FEV1/FVC>70% and FVC<80% predicted). We used Cox proportional hazard models to determine the risk of impaired lung function on subsequent mortality, after adjusting for age, race, sex and smoking status. Results: 1242 (8.0%) subjects died by the end of 1997. The overall rate of death was 8.9 per 1000 person years, but varied from 5.4/1000 among normal subjects to 42.9/1000 among subjects with GOLD Stage 3 or 4 COPD. After adjusting for covariates, all GOLD categories, along with the restricted category, predicted a higher risk of death: GOLD Stage 3 or 4, hazard ratio (HR) 5.7, 95% confidence interval (CI) 4.4, 7.3; GOLD Stage 2 HR 2.4, 95% CI 2.0, 2.9; GOLD Stage 1 HR 1.4, 95% CI 1.1, 1.6; GOLD Stage 0 HR 1.5, 95% CI 1.3, 1.8; and restricted HR 2.3, 95% CI 1.9, 2.8. Conclusion: The modified GOLD classification system of COPD predicts mortality in this cohort of middle-aged Americans followed for up to 11 years.
KW - COPD
KW - Cohort study
KW - GOLD classification
KW - Lung function
KW - Mortality
KW - Smoking
UR - http://www.scopus.com/inward/record.url?scp=29944439589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=29944439589&partnerID=8YFLogxK
U2 - 10.1016/j.rmed.2005.03.035
DO - 10.1016/j.rmed.2005.03.035
M3 - Article
C2 - 15893923
AN - SCOPUS:29944439589
SN - 0954-6111
VL - 100
SP - 115
EP - 122
JO - British Journal of Tuberculosis and Diseases of the Chest
JF - British Journal of Tuberculosis and Diseases of the Chest
IS - 1
ER -